302P Clinical benefit of adding pertuzumab in neoadjuvant HER2-positive breast cancer: Response and 5-year survival outcomes
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.731
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
3
Papers
0
Citations
0
h-index
0
i10-index
B. Vilar Anglada is an academic researcher from Institut Català d'Oncologia. The author has contributed to research in topics: Breast Cancer Treatment Studies & Head and Neck Cancer Studies & HER2/EGFR in Cancer Research.
Click to start Chat